One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Record caution: Read the product renal-toxicity warning as well as the KDIGO dose guidance. These are different clinical decisions, not a single automated recommendation.
The official label gives a qualitative reduction warning. KDIGO 2024 supplies a disease-specific indexed-eGFR reduction instruction; these differ in specificity rather than representing a universally applicable replacement label.
What to reconcile: Match lupus-nephritis context, starting exposure and retinal monitoring. Worsening renal function can also represent labeled drug toxicity, not only the underlying disease. Do not transfer the nephritis recommendation to malaria without review.
Open this note and its source referencesKDIGO 2024 recommends hydroxychloroquine or an equivalent antimalarial for patients with systemic lupus erythematosus, including lupus nephritis, unless contraindicated. In its implementation guidance, eGFR <30 mL/min/1.73 m2 calls for a hydroxychloroquine dose reduction of at least 25%.
This is disease-specific guidance, not a complete product label or a universal malaria regimen. The guideline discusses flare prevention alongside retinal and cumulative cardiac toxicity. A renal reduction does not replace assessment of the starting dose, actual product, cumulative exposure and ophthalmic monitoring.
RDM38-professional-hydroxychloroquine-plaquenil-159469d772-C1 · Source locator: KDIGO 2024 LN, printed S25 / PDF page 26; implementation guidance, visually verified
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=hydroxychloroquine-plaquenil&s1=RDM38-professional-hydroxychloroquine-plaquenil-159469d772&h1=5004c2906ef0a0606435ec2c642ebdad9b64a81e68f4027f802190709710cd44